Azafaros is focussed on the treatment of rare metabolic disorders.
The company aims at developing therapeutic agents for the treatment of rare metabolic disorders
such as lysosomal storage disorders through oral administration of azasugar compounds. These
novel, very promising agents were discovered by Professor Hans Aerts and Professor Hermen
Overkleeft at Amsterdam UMC and Leiden University, and are exclusively licensed to Azafaros.
Rare metabolic disorders
With its proprietary small molecule compounds, Azafaros will concentrate on new treatments for patients suffering from LSDs and LSD-related diseases. These compounds interfere with the metabolism of glycolipids that is disturbed in these patients and are intended to counteract the underlying pathological effects.
Olivier has a very strong industry track record most recently at Idorsia Pharmaceuticals, and before that at Actelion Pharmaceuticals and Hoffmann-La Roche. Olivier brings a broad scientific, clinical and regulatory experience as well as business insights to the Azafaros team.
Leiden, The Netherlands, July 23th, 2018 – Azafaros, a biotech company established in Leiden in the Netherlands, focusing on the development of new therapies in the field of rare metabolic disorders, today announced the closing of a seed financing round. BioGeneration...